Concepedia

Colin Hislop

CH

Statistics

Publications

12

Citations

1.2K

H-Index

11

Active since

2009

Affiliations

Anthera Pharmaceuticals (United States)(Current)

Eiger Biopharmaceuticals (United States)

Stanford University

Icahn School of Medicine at Mount Sinai

Center for Clinical Research (United States)

Colin Hislop is an author at Anthera Pharmaceuticals (United States) specializing in medicine, pharmacology, and atherosclerosis.

Top concepts

Publications per year

2009–2023

12

Publications

12

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Jordan J. Feld, Christopher Kandel, Mia J. Biondi et al. · The Lancet Respiratory Medicine · 2021 · 235 citations · Full text

Early Treatment with Pegylated Interferon Lambda for Covid-19

Gilmar Reis, Eduardo A.S. Moreira Silva, Daniela C. Medeiros Silva et al. · New England Journal of Medicine · 2023 · 167 citations · Full text

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

Richard Furie, G. Léon, Meenu Thomas et al. · Annals of the Rheumatic Diseases · 2014 · 162 citations

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla et al. · Nature Communications · 2021 · 143 citations · Full text

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Robert S. Rosenson, Colin Hislop, Daniel McConnell et al. · The Lancet · 2009 · 114 citations

, , +4

1–5 of 12